Originally published April 11.
Precision Therapeutics has launched a new product line, called BioSpeciFx, with which it hopes to personalize cancer treatments.
According to the company, BioSpeciFx comprises sets of tests that gauge genomic and proteomic markers in patients' cells. Precision Therapeutics plans to use the information generated by BioSpciFx in combination with its ChemoFx test to learn more about patients' tumors and personalize their therapy. ChemoFx assesses "the functional characteristics" of a tumor, many of which aren't accounted for via biomarker testing, to provide information about whether a patient is sensitive or resistant to chemotherapy.
"When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell," the company said in a statement.
"The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx," Sean McDonald, CEO of Precision Therapeutics, said in a statement.